

*Not for distribution or release in the United States*

## **ASX ANNOUNCEMENT**

**26 July 2023**

### **Close of Non-Renounceable Rights Offer**

---

**26 July 2023** – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) is pleased to announce the close of its Non-Renounceable Rights Offer (**Offer**) 5:00pm (Melbourne time) Tuesday, 25 July 2023. The Offer was announced on Thursday, 15 June 2023. Funds from the Offer will be used towards our accelerated growth initiatives and to realise the significant increase in production. Over the past few years, Cann have built a world-class facility at Mildura, witnessed remarkable production progress and achieved several significant milestones, including planting the biggest crop in Cann history in May 2023. Cann firmly believe that this Offer will enable the Company to accelerate growth trajectory and strengthen market position, including by enabling Cann to pursue an increase in production to reach 12.5 tonnes on an annualised basis.

The Company will release the results of the Offer on Friday, 28 July 2023.

#### **Further information**

For further information regarding the Offer please contact Ms Deborah Ambrosini, Cann Group Limited Company Secretary on +61 3 9095 7088.

**Authorised for release by Deborah Ambrosini, Company Secretary Cann Group Limited.**

#### **For all media enquiries please contact:**

Jackson Paine  
Corporate Communications Manager  
+61 439 492 955  
[jackson.paine@canngrouponlimited.com](mailto:jackson.paine@canngrouponlimited.com)

#### **For all other information please contact:**

Peter Koetsier  
CEO  
Cann Group Limited  
+61 3 9095 7088  
[contact@canngrouponlimited.com](mailto:contact@canngrouponlimited.com)

Deborah Ambrosini  
CFO & Company Secretary  
Cann Group Limited  
+61 3 9095 7088  
[deborah.ambrosini@canngrouponlimited.com](mailto:deborah.ambrosini@canngrouponlimited.com)

#### **About Cann Group**

Cann Group Limited (ABN 25 603 949 739) is enhancing patients' lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

Learn more at: [www.canngrouponlimited.com](http://www.canngrouponlimited.com) | [www.satipharm.com](http://www.satipharm.com)